Market capitalization | €11.60b |
Enterprise Value | €11.90b |
P/E (TTM) P/E ratio | 28.22 |
EV/FCF (TTM) EV/FCF | 76.07 |
EV/Sales (TTM) EV/Sales | 3.13 |
P/S ratio (TTM) P/S ratio | 3.05 |
P/B ratio (TTM) P/B ratio | 3.00 |
Dividend yield | 0.86% |
Last dividend (FY23) | €0.85 |
As a Free StocksGuide user, you can view scores for all 6,897 stocks worldwide.
16 Analysts have issued a bioMerieux SA forecast:
16 Analysts have issued a bioMerieux SA forecast:
Jun '24 |
+/-
%
|
||
Revenue | 3,807 3,807 |
3%
3%
|
|
Gross Profit | 2,016 2,016 |
4%
4%
|
|
EBITDA | 826 826 |
3%
3%
|
EBIT (Operating Income) EBIT | 487 487 |
8%
8%
|
Net Profit | 411 411 |
7%
7%
|
In millions EUR.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
bioMérieux SA engages in the provision of in vitro diagnostic solutions, which determine the source of disease and contamination. The firm develops testing. detection, and other laboratory system for the analysis of cancer, diseases, and infections caused by bacteria, virus, and fungi. The company was founded Alain Mérieux in 1963 and is headquartered in Marcy l'Etoile, France.
Head office | France |
CEO | Pierre Boulud |
Employees | 14,651 |
Founded | 1967 |
Website | www.biomerieux.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.